Shortlisted finalists for the 2015 CPhI Pharma Awards announced
23 September 2015 | By Victoria White
This year’s entries include innovations and new service offerings from across the entire spectrum of the pharmaceutical supply chain...
List view / Grid view
News
MorphoSys provides update on MOR202 in multiple myeloma
23 September 2015 | By Victoria White
The Company said that the clinical data from a Phase 1/2a study confirm the very good overall safety profile of the fully human HuCAL antibody...
EC approves Zalviso for post-operative pain
22 September 2015 | By Victoria White
Zalviso is designed to offer sustained (for up to 72 hours) pain relief for acute moderate-to-severe post-operative pain...
Successful Phase 1 results for cardiometabolic disease drug PXS-4728A
22 September 2015 | By Victoria White
PXS-4728A is a highly selective inhibitor of an enzyme and adhesion protein which reduces inflammation and oxidative stress...
FDA awards $19 million to boost rare disease treatment development
22 September 2015 | By Victoria White
The FDA awards the grants through the Orphan Products Grants Programme to encourage clinical development of treatments for use in rare diseases...
Top-line Phase 3 results for ulcerative colitis treatment tofacitinib announced
22 September 2015 | By Victoria White
Both Phase 3 studies met their primary endpoints as measured by the proportion of patients receiving tofacitinib in remission at Week 8 compared to patients receiving placebo...
New data will be presented for Roche’s Esbriet in idiopathic pulmonary fibrosis at European Respiratory Society Congress 2015
21 September 2015 | By Roche
Roche announced that new Esbriet® (pirfenidone) data analyses in idiopathic pulmonary fibrosis (IPF) will be presented at the European Respiratory Society (ERS) congress in Amsterdam, 26-30 September 2015...
Bezlotoxumab reduces C. difficile infection recurrence in Phase 3 trials
21 September 2015 | By Victoria White
Merck plans to submit new drug applications seeking regulatory approval of bezlotoxumab in the US, EU and Canada in 2015...
FDA approves Vraylar for schizophrenia and bipolar disorder
21 September 2015 | By Victoria White
The FDA approval is based on the results of three 3-week controlled trials in adults with bipolar I disorder and three 6-week placebo-controlled trials in adults with schizophrenia...
Complacency not an option when it comes to Polio
21 September 2015 | By Victoria White
Following news that a British man had been producing the Polio virus for 30 years, experts say high immunisation coverage should keep us covered, but changes to immunisation strategies may be required...
EC approves Shire’s ADHD treatment Intuniv
21 September 2015 | By Victoria White
The EC has granted Marketing Authorisation for Intuniv for the treatment of ADHD in children and adolescents for whom stimulants are not suitable...
Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement
17 September 2015 | By Black Swan
Market Publishers and Black Swan Analysis signed a partnership agreement for quality market research promotion on the Internet...
Xultophy trial shows improvements in patient-reported outcomes
17 September 2015 | By Victoria White
The DUAL V trial evaluated the efficacy and safety of Xultophy compared to insulin glargine U100 in adults with type 2 diabetes...
Sandoz opens new state-of the-art BioInject facility in Schaftenau
17 September 2015 | By Victoria White
BioInject will be used to manufacture pre-filled syringes and devices for both Sandoz’s biosimilars and Novartis Pharma’s novel biologics...
Andor launches KOMET 7 Software for the Comet Assay
17 September 2015 | By Andor Technology
The most advanced and powerful software solution for analysis, data management and presentation of comet assay samples...
